BC Cancer Agency

STEMCELL Technologies President and CEO Dr. Allen Eaves Appointed to the Order of Canada

Retrieved on: 
Jeudi, décembre 29, 2022
Research, Public Policy, Government, Stem Cells, Biotechnology, Other Health, White House, Federal Government, Health, General Health, Science, BC Cancer Agency, Mentorship, Friends, Research, Hope, University, Multimedia, Stemcell Technologies, Science, Acadia University, Biology, Development, Vancouver General Hospital, Research and development, Heart, Internal medicine, Dalhousie University, Oncology, Order, The Right Honourable, Senior, Hospital, Doctor of Philosophy, Management, Medical device

STEMCELL Technologies President and CEO Dr. Allen Eaves has been appointed to the Order of Canada -- one of the nation’s highest forms of recognition. (Photo: Business Wire)

Key Points: 
  • STEMCELL Technologies is proud to announce its President and CEO, Dr. Allen Eaves, has been appointed to the Order of Canada by Her Excellency the Right Honourable Mary Simon, the Governor General of Canada.
  • View the full release here: https://www.businesswire.com/news/home/20221229005015/en/
    STEMCELL Technologies President and CEO Dr. Allen Eaves has been appointed to the Order of Canada -- one of the nation’s highest forms of recognition.
  • (Photo: Business Wire)
    One of the nation’s highest forms of recognition, the Order of Canada recognizes people who make extraordinary contributions to Canadian society.
  • “Being appointed to the Order of Canada is an honour of a lifetime, and I am grateful for the countless colleagues, mentors, friends, and family members who supported me throughout my career,” Dr. Eaves said.

Qu Biologics and Karolinska Institute Initiate Important New Collaboration to Validate Molecular Mechanisms of Qu Biologics’ First-in-Class Immunotherapy Platform

Retrieved on: 
Mercredi, décembre 14, 2022
Site, BC Cancer Agency, Ulcerative colitis, SSI, Associate, CD, Inflammation, Partnership, Lung cancer, Science, Epithelium, News, Cancer, Biotechnology, Inflammatory Bowel Diseases, KI, Infection, GI, Ethics, Crohn's disease, Conditional sentence, Fuxing (train), Pathology, Gene, HIV disease progression rates, Karolinska Institute, IBD, Disease, SSIS, Precision medicine, Immunosenescence, Medical laboratory, Division, Patient, Medical imaging, Vaccine, Pharmaceutical industry

Epithelial cells on mucosal surfaces are an important immune interface between microbial invaders and human tissue.

Key Points: 
  • Epithelial cells on mucosal surfaces are an important immune interface between microbial invaders and human tissue.
  • Loss of epithelial barrier function is commonly seen in diseases associated with chronic inflammation and can be exceedingly challenging to resolve.
  • Despite the arsenal of immune suppressive medication used to treat IBD, most patients experience disease progression.
  • Qu Biologics does not assume any obligation to update any forward-looking statements except as required by law.

Personalis Reports Third Quarter 2022 Financial Results

Retrieved on: 
Mercredi, novembre 2, 2022
Oncology, Health, Genetics, Health Technology, Pharmaceutical, Biotechnology, Security (finance), Goal, MRD, Neoplasm, U.S. Securities and Exchange Commission, Efficiency, SEC, Genomics, Cancer, Research, Blood, UC San Diego Health, Result, Nasdaq, SVP, COVID-19, Intellectual property, VA, Financial condition report, Immune system, PSNL, College of American Pathologists, Telephone, Duke University, MVP, Adoption, BC, Investment, College, U.S. Department of Defense Strategy for Operating in Cyberspace, Clinical Laboratory Improvement Amendments, Private Securities Litigation Reform Act, Moores Cancer Center, Patient, BC Cancer Agency, NeXT, Forward-looking statement, New Center, Detroit, Analysis, Medical imaging, Pharmaceutical industry, Cryptocurrency, Fine chemical, Chief Justice of Hungary, Natera

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2022.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2022.
  • Personalis, Inc. is a leader in advanced cancer genomics, enabling the next generation of precision cancer therapies and diagnostics.
  • For more information, visit the Personalis website and News Center , and follow Personalis on LinkedIn and Twitter .
  • Actual results may differ materially from the results predicted, and reported results should not be considered an indication of future performance.

Qu Biologics to Receive Additional Funding to Support Innovative New Treatment to Restore Innate Immune Function in the Elderly

Retrieved on: 
Lundi, octobre 17, 2022
News, Risk, Urinary tract infection, COPD, Infection, Achievement, VP, NRC, SSIS, SSI, Immunity, Immunosenescence, Biotechnology, Asthma, Research, BC Cancer Agency, Mortality, Cancer, Lung cancer, National Research Council, Disease, CEO, Site, Innovation, GLOBE, Ulcerative colitis, Forward-looking statement, Ageing, COVID-19, Conditional sentence, Vaccine, Pharmaceutical industry

Innate immunity declines with age, leaving the elderly at significantly higher risk of developing severe respiratory infections (like COVID-19), cancer, and other diseases.

Key Points: 
  • Innate immunity declines with age, leaving the elderly at significantly higher risk of developing severe respiratory infections (like COVID-19), cancer, and other diseases.
  • This support from NRC IRAP for the clinical development of Qu Biologics unique made-in-Canada solution addresses the significant unmet need for immune protection in the elderly.
  • Dr. Ted Steiner, Qu Biologics Chief Medical Officer, Infectious Diseases, added, This trial, if successful, would be transformative.
  • Qu Biologics does not assume any obligation to update any forward-looking statements except as required by law.

Pacylex Pharmaceuticals Announces Progress on Early Phase Clinical Trials of PCLX-001 in Patients

Retrieved on: 
Jeudi, septembre 29, 2022
Apoptosis, BC Cancer Agency, Blood, Safety, Trial of the century, Exposition, Research, CHUM, Breast cancer, Breast Cancer Research and Treatment, Society, ASH, American Association, Treatment, Environment, Survival, Patient, Leukemia, NMT, Princess Margaret Hospital, CEO, Protein, Silver, Toxic leukoencephalopathy, Nature Communications, Lung, AML, Association, University, Lymphoma, Cell death, DLBCL, Pharmaceutical industry, Cancer

Edmonton, Alberta--(Newsfile Corp. - September 29, 2022) - Pacylex Pharmaceuticals has dosed 16 patients in the early phase clinical trials of the company's new cancer drug, PCLX-001.

Key Points: 
  • Edmonton, Alberta--(Newsfile Corp. - September 29, 2022) - Pacylex Pharmaceuticals has dosed 16 patients in the early phase clinical trials of the company's new cancer drug, PCLX-001.
  • In December 2021, Pacylex announced the results of the first patients dosed with PCLX-001 at the American Society of Hematology (ASH) Annual meeting and Exposition.
  • Pacylex has safely completed 4 dose cohorts reaching target drug exposure levels in patients expected to provide benefit in leukemia and lymphoma.
  • Pacylex began clinical studies of the drug in Canada in September 2021 and is currently seeking funds for Phase 2 of clinical trials.

Qu Biologics to Launch Phase 2B Clinical Trial to Assess Reduction of Postoperative Immune Suppression and Disease Progression in Patients with Late-Stage Colorectal Cancer

Retrieved on: 
Lundi, septembre 26, 2022
BC Cancer Agency, VP, Center, Ethics, Sunnybrook Health Sciences Centre, Conditional sentence, Site, Hope, Colorectal cancer, GI, Innovation, SSIS, SSI, Achievement, Biomolecular Object Network Databank, Immunotherapy, Survival, Ottawa Hospital Research Institute, Patient, Infection, Lung cancer, NK, Cancer, Forward-looking statement, Gastroenterology, Health Canada, Liver disease, Ulcerative colitis, Immunosenescence, CEO, Liver, Clinical trial, Sunnybrook Research Institute, Biotechnology, GLOBE, HIV disease progression rates, Immune system, Medical imaging, Vaccine, Pharmaceutical industry

Major surgery results in immune paralysis in the days following surgery that can contribute to cancer growth and metastases, leading to poor outcomes for cancer patients undergoing surgical treatment.

Key Points: 
  • Major surgery results in immune paralysis in the days following surgery that can contribute to cancer growth and metastases, leading to poor outcomes for cancer patients undergoing surgical treatment.
  • Dr. Hal Gunn, CEO of Qu Biologics, stated, A majority of patients diagnosed with cancer undergo surgery in the hope of cure.
  • This exciting study is designed to test whether we can prevent that postoperative immune suppression resulting in improved outcomes and survival.
  • Qu Biologics has completed four Phase 2 studies in lung cancer, Crohns disease, and ulcerative colitis.

BC Cancer Foundation Launches Historic $500 Million Fundraising Campaign to Take Cancer Research and Care Beyond Belief

Retrieved on: 
Mercredi, septembre 21, 2022
People, Blood, Â, Provincial Health Services Authority, Ovarian cancer, Beyond Belief, BC Cancer Agency, Partnership, BC, Government, Patient, Clinical trial, History, CEO, Technology, Chair, Foundation, Science, Research, GLOBE, Cancer, Pharmaceutical industry, Dentistry, Oil, Birth control

On behalf of everyone at BC Cancer, wed like to thank the people of British Columbia for supporting our work through this important campaign, said Dr. Kim Chi, Chief Medical Officer, BC Cancer.

Key Points: 
  • On behalf of everyone at BC Cancer, wed like to thank the people of British Columbia for supporting our work through this important campaign, said Dr. Kim Chi, Chief Medical Officer, BC Cancer.
  • This is the most exciting time in the history of cancer research and B.C.
  • The BC Cancer Foundation supports attracting and retaining world-class experts at BC Cancers Research Institute and six cancer centres by establishing fellowships, creating Chair positions to support research, and funding clinical trials.
  • To learn more about the Beyond Belief campaign, its regional impacts or to donate, please visit: GoBeyondBeliefBC.ca
    The BC Cancer Foundation is the fundraising partner of BC Cancer and the largest philanthropic funder of cancer research and care in B.C.

POINT Biopharma to Publish Abstract at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial

Retrieved on: 
Jeudi, août 18, 2022
ESMO, Prostate cancer, Risk, United Kingdom, Forward-looking statement, GLOBE, Actinium-225, Private Securities Litigation Reform Act, SEC, Cancer, SPLASH, DRS, BC Cancer Agency, COVID-19, Company, MCRPC, Tulane School of Professional Advancement, NASDAQ, Intention, PSMA, University, Patient, MD, Progression-free survival, Pharmacokinetics, Terminology, Pharmaceutical industry

INDIANAPOLIS, Aug. 18, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced the company will be publishing an abstract at ESMO Congress 2022, which takes place in Paris, France on September 9-13, 2022.

Key Points: 
  • Sartor and Chi were joined by the Companys executive leadership team including Dr. Sherin Al-Safadi, VP Medical Affairs.
  • The randomization phase of the study is expected to enroll approximately 400 participants across North America, Europe, and the United Kingdom.
  • Participants will be randomized 2:1 with participants in arm A receiving PNT2002 and participants in arm B receiving either abiraterone or enzalutamide.
  • About POINT Biopharma Global Inc.
    POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer.

Personalis in Partnership with BC Cancer to Assess Clinical and Economic Benefits of ctDNA for Colorectal and Pancreatic Cancers

Retrieved on: 
Lundi, août 15, 2022
Research, Genetics, Clinical Trials, Health Technology, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Genomics, U.S. Securities and Exchange Commission, Adoption, Survival, BC, Mortality, MRD, Recurrence, Senior, Assistant, Diagnosis, College, Form, Drug resistance, Cancer, Leadership, Provincial Health Services Authority, Incidence, Efficiency, Form S-3, Research, Neoplasm, Patient, Quality of life, DNA, Twitter, Education, Program, University, College of American Pathologists, RUO, Â, Clinical Laboratory Improvement Amendments, Circulating tumor DNA, Gastrointestinal cancer, Palliative care, BC Cancer Agency, MD, LinkedIn, Rehabilitation, Immune system, Medical imaging, Chief Justice of Hungary

Identification and tracking of MRD is an emerging focus in the clinical care of patients with gastrointestinal cancers such as colorectal and pancreatic cancer, which may improve overall clinical management throughout a patients journey.

Key Points: 
  • Identification and tracking of MRD is an emerging focus in the clinical care of patients with gastrointestinal cancers such as colorectal and pancreatic cancer, which may improve overall clinical management throughout a patients journey.
  • Approximately 220 patients will be recruited for this study from across British Columbia to assess how ctDNA can improve cancer care delivery.
  • Personalis, Inc. is a leader in advanced cancer genomics, enabling the next generation of precision cancer therapies and diagnostics.
  • To enable cancer sequencing, Personalis' Clinical Laboratory was built with a focus on clinical accuracy, quality, big data, scale and efficiency.

POINT Biopharma to Host Investor Education Event, “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm”, on August 18, 2022

Retrieved on: 
Lundi, août 8, 2022
FDA, III, Prostate cancer, Dean (education), Clinical Genitourinary Cancer, Risk, United Kingdom, Forward-looking statement, GLOBE, ORR, Actinium-225, Private Securities Litigation Reform Act, SEC, Cancer, SPLASH, Medicine, Tulane University School of Medicine, NRG, Laborde, Research, Abiraterone acetate, Patient, NCI, Company, COVID-19, MCRPC, II, NASDAQ, Intention, GU, National Cancer Institute, Oncology, Docetaxel, BC Cancer Agency, MD, RPF, Clinical Science (journal), National, Pharmacokinetics, Terminology, Pharmaceutical industry, Medical imaging, Epidemiology

INDIANAPOLIS, Aug. 08, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, announced that next week, on Thursday, August 18, 2022 at 12:00 PM ET, the Company will be presenting a 45-minute educational webinar entitled “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm”.

Key Points: 
  • He is also a past member of the National Cancer Institute Board of Scientific Counselors (Clinical Sciences and Epidemiology).
  • This includes phase I, II and III clinical trials, therapeutic use of antisense oligonucleotides and mechanisms of treatment resistance.
  • Information about POINT Biopharma Global Inc.s Phase 3 SPLASH trial for metastatic castrate resistant prostate cancer (mCRPC) patients can be found at https://www.splashtrial.com/ .
  • The forward-looking statements in this press release represent our views as of the date of this press release.